INTUITIVE SURGICAL INC
INTUITIVE SURGICAL INC (ISRG) Stock News
The latest ISRG headlines and market coverage — 9 recent stories, updated throughout the day.
- Zacks Investment Research·
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside
Intuitive Surgical, the leader in surgical robotics, has fallen 30% from early 2025 highs but is poised for a technical breakout ahead of its Q3 earnings release on October 20. With strong fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and ~43% upside potential to all-time highs, the stock earns a Zacks Rank #2 (Buy) rating. The company projects 15% Q3 revenue growth and 17% revenue growth for 2026.
- Zacks Investment Research·
Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know
Intuitive Surgical (ISRG) outperformed the broader market on October 15, 2026, closing up 1.81% and gaining 9.93% over the past month. The company has a Zacks Rank #2 (Buy) rating with expected Q3 EPS growth of 8.75% and full-year earnings growth of 20.27%. However, the stock trades at a premium valuation with a Forward P/E of 39.15 compared to the industry average of 23.25.
- Zacks Investment Research·
ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption.
- Zacks Investment Research·Neutral
Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know
Intuitive Surgical (ISRG) gained 2.41% to $414.52 on October 7, 2026, outperforming a declining market. The stock has surged 15.59% over the past month, significantly outpacing the Medical sector's 4.73% loss. Upcoming earnings on October 20 are expected to show 8.75% EPS growth and 14.98% revenue growth year-over-year. However, the stock carries a Zacks Rank #3 (Hold) rating with a premium Forward P/E of 37.71 versus the industry average of 23.11.
- Zacks Investment Research·
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.
- Zacks Investment Research·
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical published a large meta-analysis in Annals of Surgery Open showing da Vinci robotic-assisted surgery delivered significant perioperative improvements across 13 benign procedures compared to laparoscopic and open surgery. Results included 54% lower conversion to open surgery, 69% reduction in blood transfusions versus open surgery, and 46% fewer 30-day complications. The da Vinci 5 platform continues gaining momentum with over 1,700 systems installed. ISRG stock gained ~8% following the announcement and currently holds a Zacks Rank #3 (Hold).
- Zacks Investment Research·Neutral
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
Intuitive Surgical (ISRG) gained 2.38% to $377.94 on September 14, 2026, outperforming a declining broader market. The company is expected to report EPS of $2.61 (up 8.75% YoY) and quarterly revenue of $2.88 billion (up 14.98% YoY). However, the stock has declined 6.43% over the past month and carries a Zacks Rank #3 (Hold) rating with a premium valuation at 34.39 Forward P/E versus the industry average of 21.78.
- Zacks Investment Research·
The Zacks Analyst Blog Highlights FANUY, ABBNY, KYCCF, NVDA, ISRG, ILMN, NOVT, BOTZ, ROBO, ROBT and IBOT
Zacks highlights the robotics and AI sector as a major growth opportunity, with the general-purpose robotics market projected to grow from under $1 billion in 2025 to $370 billion by 2040. The article examines key industry players including Fanuc, ABB, Keyence, NVIDIA, Intuitive Surgical, and Illumina, and recommends four robotics-focused ETFs (BOTZ, ROBO, ROBT, IBOT) as diversified investment vehicles to capitalize on this trend.
- Zacks Investment Research·
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.